Shots:
- The P-III (BRUIN CLL-322) trial assessed Jaypirca + venetoclax & rituximab vs venetoclax & rituximab in r/r chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), with both arms treated ~2yrs. followed by therapy-free period until disease progression
- The trial met its 1EP, demonstrating improved PFS per IRC, with consistent results across clinically relevant subgroups & regardless of prior covalent BTK inhibitor exposure
- The OS data was immature during analysis, but showed a favorable trend. Results will be presented at a future conference & are planned to be submitted to regulators later this year for label expansion
Ref: Eli Lilly | Image: Eli Lilly | Press Release
Related News: Eli Lilly Launches Foundayo (Orforglipron) for Weight Loss in the US
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
